Neos Therapeutics (NASDAQ:NEOS) released its earnings results on Friday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03), MarketWatch Earnings reports. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $14.80 million. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%.

NEOS traded up $0.01 during trading on Friday, reaching $2.59. 651,079 shares of the company’s stock were exchanged, compared to its average volume of 621,268. Neos Therapeutics has a 1 year low of $2.27 and a 1 year high of $11.69. The firm has a market capitalization of $83.38 million, a PE ratio of -0.97 and a beta of 0.44.

A number of research firms recently commented on NEOS. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 target price on shares of Neos Therapeutics in a research note on Friday. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. Zacks Investment Research raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Finally, Wells Fargo & Co reduced their price target on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.50.

In other Neos Therapeutics news, Director Alan L. Heller purchased 43,478 shares of Neos Therapeutics stock in a transaction on Thursday, November 8th. The stock was bought at an average cost of $2.30 per share, with a total value of $99,999.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Neos Therapeutics (NEOS) Announces Earnings Results, Misses Expectations By $0.03 EPS” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: Price to Earnings Ratio (PE)

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with's FREE daily email newsletter.